PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pharmacist-Led Deprescribing Halves Inappropriate Medications in Older Cancer Patients

deprescribingpolypharmacypotentially inappropriate medicationsSTOPP criteriaBeers criteriageriatric oncologyolder adultscancerclinical pharmacistcomprehensive geriatric assessmentsystematic reviewmeta-analysis Geriatrics
Also in Oncology

Background Information

Deprescribing cuts inappropriate medication use in cancer care for older adults.

Deprescribing potentially inappropriate medications (PIMs) in older adults with cancer can reduce morbidity and mortality, but its effectiveness remains unclear. The review found that deprescribing interventions reduced PIM use with a pooled relative risk (RR) of 0.49 in a meta-analysis of three studies. Deprescribing in geriatric oncology is feasible and reduces PIM exposure, but more robust studies are needed to validate broader patient-centered outcomes. Deprescribing reduces PIMs in older adults with cancer but evidence gaps persist.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Maleki S, Foo J, Zamani M, Mejia A, Soo WK, Turner JP, Kirkpatrick C

Citation: Maleki S, Foo J, Zamani M, et al. Deprescribing interventions in older adults with cancer: A systematic review and meta-analysis. Journal of geriatric oncology. 2026;18(1):104120. doi:10.1016/j.jgo.2026.104120

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.